Acupuncture Combined With Nimodipine for Prevention of Post-stroke Dementia

NCT ID: NCT06007573

Last Updated: 2023-08-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-01

Study Completion Date

2023-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To observe the clinical efficacy of TCM acupuncture combined with western medicine nimodipine for prevention of post-stroke dementia by comparing with clinical conventional treatment methods.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-stroke Dementia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

treatment group

On the basis of the control group treatment, the treatment group also adopted the acupuncture treatment

Group Type EXPERIMENTAL

The control group received oral nimodipine tablets

Intervention Type DRUG

The control group received oral nimodipine tablets

control group

The control group received oral nimodipine tablets

Group Type OTHER

The control group received oral nimodipine tablets

Intervention Type DRUG

The control group received oral nimodipine tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The control group received oral nimodipine tablets

The control group received oral nimodipine tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Definite ischemic stroke or hemorrhagic stroke confirmed by head CT / MRI examination
2. Memory or cognitive and executive dysfunction. Cognitive dysfunction will be determined after the mini mental state evaluation (MMSE) score
3. Age limited to 40-85 years, irrespective of gender
4. Stable condition, clear consciousness, no aphasia, oral medication available
5. No major comorbidity, no major depression
6. Consent and signed patient informed consent

Exclusion Criteria

1. Had serious medical conditions, such as heart, liver, kidney, or endocrine disease
2. Aphasia or hearing impairment
3. Participants in other clinical trials
4. Patients currently on medication to improve cognitive function
Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Department of acupuncture and massage, Nanling Hospital of traditional Chinese Medicine, Nanling County, Wuhu City, Anhui Province

UNKNOWN

Sponsor Role collaborator

Yuzhen Pan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yuzhen Pan

DOCTOR

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Second Affiliated Hospital of Anhui University of Chinese Medicine

Hefei, Anhui, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-zj-21

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.